InteRNA Technologies Receives Notice of Allowance from USPTO
News Oct 16, 2012
InteRNA Technologies B.V. has announced that the United States Patent and Trademark Office (USPTO) has issued the Company a notice of allowance on a patent application covering miRNA sequences, identified through deep sequencing of several different mouse, monkey and human samples, including different tumor samples.
The allowable product claims protect miRNA-3157, homologues, precursors and mimics thereof.
In a second pending patent application, miRNA-3157, homologues, precursors and mimics thereof are claimed as a therapy against melanoma.
A mimic of miRNA-3157 is entering preclinical development and represents InteRNA's lead product in its B-Raf/melanoma program.
"This issuance of the USPTO confirms our unique approach to identification and validation of miRNAs as drug targets and further development towards the clinic", said Roel Schaapveld, CEO of InteRNA Technologies.
Schaapveld continued, "It further subscribes our patent strategy and greatly strengthens our intellectual property position on miRNA drug candidates."
The latest data on miRNA-3157 as drug candidate for the treatment of human melanoma will be presented at the Society for Melanoma Research 2012 Congress, November 8-11 in Hollywood, CA, USA.
Sphere Fluidics and Geneva Biotech Receive Eurostars Genome Editing GrantNews
€1.6 million grant will support ‘precise docking of very large DNA cargoes in genomes’ project.READ MORE
RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis BNews
The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.READ MORE
A More Effective Alternative to RNAi, CRISPR for Studying Protein FunctionNews
Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.READ MORE